Joe Jimenez and Mark Fishman target $400M for third fund after leaving Novartis

Kyle LaHucik

Senior Reporter

Former Novartis CEO Joe Jimenez and research leader Mark Fishman are fundraising again for their life sciences firm Aditum Bio, which in-licenses translational-stage drugs and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Joe Jimenez and Mark Fishman target $400M for third fund after leaving Novartis

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Joe Jimenez and Mark Fish­man tar­get $400M for third fund af­ter leav­ing No­var­tis

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Joe Jimenez and Mark Fishman target $400M for third fund after leaving Novartis